by Barry101 | Feb 12, 2019 | Press Release
To be a stockholder of record, investors are advised to own Hemispherx stock by 4:00 PM ET, Tuesday, February 12, 2019 to account for T+2 settlement timingRecord date established as Thursday, February 14, 2019OCALA, Fla., Feb. 12, 2019 — Hemispherx Biopharma,...
by Barry101 | Feb 11, 2019 | Press Release
OCALA, Fla., Feb. 11, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on unmet medical needs in immunology and oncology, announced today the start at the UPMC Hillman Cancer Center in Pittsburgh, PA of a new clinical...
by Barry101 | Feb 6, 2019 | Press Release
OCALA, Fla., Feb. 06, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today provided an...
by Barry101 | Jan 31, 2019 | Press Release
OCALA, Fla., Jan. 31, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc. CEO Tom Equels this week provided investors at NobleConXV with an update on the company’s ongoing work in immuno-oncology and in Myalgic Encephalomyelitis/Chronic Fatigue...
by Barry101 | Jan 24, 2019 | Press Release
OCALA, Fla., Jan. 24, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that CEO Thomas K. Equels will present at...
by Barry101 | Jan 23, 2019 | Press Release
OCALA, Fla., Jan. 23, 2019 — (NYSE American: HEB) – Hemispherx Biopharma Inc., an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today that CEO Thomas K. Equels will present at...
